Pyxis Oncology grants director 34,500 stock options

Q: What option award did PYXS director Rachel Humphrey receive?

Rachel Humphrey received 34,500 stock options, exercisable for common stock at $1.66 per share.

The options have an expiration date of November 6, 2036.

Available on EDGAR 11/06/2026 - 06:09 PM EST Accepted by SEC EDGAR 11/06/2026 - 06:08 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pyxis Oncology, Inc. director Rachel Humphrey received a grant of 34,500 stock options on November 6, 2026, exercisable for common stock at $1.66 per share. The options vest in equal monthly installments through December 31, 2026, subject to her continued service through each applicable vesting date.

Insider Trade Summary

Grant/Award: 34,500 shares

Grant/Award 1 txn

Insider HUMPHREY RACHEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	34,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 34,500 options (Direct)

Footnotes (1)

F1. The shares subject to this option will vest in equal monthly installments through December 31, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Stock options granted: 34,500 options Exercise price: $1.66 per share Underlying common shares: 34,500 shares +2 more

5 metrics

Stock options granted 34,500 options Granted November 6, 2026

Exercise price $1.66 per share For the stock options granted

Underlying common shares 34,500 shares Shares subject to the option

Vesting through December 31, 2026 Equal monthly installments, subject to continued service through each applicable vesting date

Expiration date November 6, 2036 Stock options

Key Terms

Stock Option (Right to Buy), exercise price, vest in equal monthly installments

3 terms

Stock Option (Right to Buy) financial

"grant of Stock Option (Right to Buy)"

exercise price financial

"exercisable for common stock at $1.66 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"will vest in equal monthly installments through December 31, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did PYXS director Rachel Humphrey receive?

Rachel Humphrey received 34,500 stock options, exercisable for common stock at $1.66 per share.

When do Rachel Humphrey’s PYXS options expire?

The options have an expiration date of November 6, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUMPHREY RACHEL

(Last)

(First)

(Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.66	11/06/2026		A		34,500		⁽¹⁾	11/06/2036	Common Stock	34,500	$0	34,500	D

Explanation of Responses:

1. The shares subject to this option will vest in equal monthly installments through December 31, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Humphrey Rachel	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR